Summary

Overview
The global silent cancer therapeutics market reached US$ 149.2 billion in 2023 and is expected to reach US$ 295.1 billion by 2031 growing with a CAGR of 8.9% during the forecast period 2024-2031.
Silent cancers do not have any initial symptoms. It is because most of these cancers affect the internal organs such as the stomach, intestines, liver, pancreas, lungs, or bladder. They affect organs and other parts deep inside the body, so it is not easy to find them during a regular physical examination. In most of the cases, patients may have no symptoms of cancer until the advanced stages. The doctor diagnoses silent cancers, usually in their advanced stages.
However, in some cases, these cancers are detected during the diagnosis of other conditions. Therefore, high–risk individuals must regularly screen themselves to determine the presence of these cancers at an early stage. Some silent cancers include breast cancer, ovarian cancer, colorectal cancer, prostate cancer, and lung cancer.
Market Dynamics: Drivers
Increasing prevalence of silent cancer
The demand for the global silent cancer therapeutics market is driven by multiple factors. The incidence of silent cancers, such as prostate, ovarian, and liver cancers, is on the rise due to factors like aging populations, unhealthy lifestyles, and environmental exposures. Cervical cancer is the fourth most common cancer in women globally with around 660,000 new cases and around 350, 000 deaths in 2022.
Moreover, key players in the industry's innovative launches and awareness programs regarding silent cancer would drive this market growth. For instance, in March 2024, UNICEF launched the new Cervical Cancer Toolkit Matters for Women's Health. Women in lower-income countries are likely to benefit most as UNICEF offers a complete supply solution for cervical cancer programs.
This toolkit contains novel HPV vaccines, high-performing diagnostic tests for HPV, and portable devices for pre-cervical cancer treatment which are very well-suited for low-resource settings.
Also, in September 2023, News18 Network, Federal Bank Hormis Memorial Foundation, and Tata Trusts, all three organizations renowned for their dedication to meaningful and impactful initiatives, will jointly unveil 'Sanjeevani-United Against Cancer'.
'Sanjeevani' aims to raise awareness and encourage conversations around the silent cancer epidemic, and to alleviate fears that often accompany this disease. The collaborative effort seeks to drive positive sentiments towards early and consistent health tests, tumor management, and symptom recognition, all crucial aspects in the battle against cancer.
Restraints
Factors such as the high treatment cost, side effects & toxicity associated with the treatment, lack of awareness among individuals, late diagnosis & advanced disease, and stringent regulatory requirements, are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The global silent cancer therapeutics market is segmented based on cancer type, treatment, end-users, and region.
The prostate cancer segment accounted for approximately 45.5% of the global silent cancer therapeutics market share
The prostate cancer segment is expected to hold the largest market share over the forecast period. Prostate Cancer also comes with fewer warning signs. It is one of the rarer forms of GI cancer. One of the biggest challenges with Prostate Cancer diagnosis is that its symptoms are often vague and can be easily associated with other less serious GI conditions.
This often leads to misdiagnosis and delayed diagnosis. The chance of being diagnosed with prostate cancer increases rapidly after age 50. About 6 in 10 of all prostate cancers are diagnosed in men over the age of 65.
Moreover, key players in the industry product approval, financial investments, and awareness programs would propel this segment's growth in the market. For instance, in March 2023, Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body.
Also, in March 2023, Artera launched with $90M to personalize prostate cancer therapy. The company will use the funds to circulate its ArteraAI Prostate Test and to develop tests to support individualized therapy options for other cancers.
Similarly, in March 2024, TV news presenter Nick Owen launched a podcast encouraging men to discuss Breast Cancer and its symptoms.
Geographical Analysis
North America accounted for approximately 41.2% of the global silent cancer therapeutics market share
North America region is expected to hold the largest market share over the forecast period owing to the rising number of cancer cases & deaths, well-advanced healthcare infrastructure, and favorable reimbursement policies that would drive this market growth in this region.
According to the JAMA Network Open research publication in April 2021, the rising number of silent cancer cases in the U.S. would propel this market growth in this region. Breast (364 000 cases) with melanoma (219 000 cases) becoming the second most common cancer; lung, third (208 000 cases); colorectal remaining fourth (147 000 cases); and prostate cancer dropping to the fourteenth most common cancer (66 000 cases).
In addition, several death cases would drive this market growth. Lung cancer (63 000 deaths) was estimated to continue as the leading cause of cancer-related death in 2040, with Prostate Cancer (46 000 deaths) and liver and intrahepatic bile duct cancer (41 000 deaths) surpassing colorectal cancer (34 000 deaths) to become the second and third most common causes of cancer-related death, respectively. Breast cancer (30,000 deaths) was estimated to decrease to the fifth most common cause of cancer death.
Moreover, key players in the industry drug launches and approvals would drive this market growth in this region. For instance, in April 2024, AstraZeneca and Daiichi Sankyo's ENHERTU (fam-trastuzumab deruxtecan-nxki) was approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic therapy and have no satisfactory alternative treatment options.
Also, in July 2023, Natco Pharma is seeking the U.S. Food and Drug Administration’s (U.S. FDA) approval for its generic version of Janssen’s cancer drug Erdafitinib Tablets 3 mg, 4 mg, and 5 mg strengths. Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC)
Market Segmentation
By Cancer Type
• Ovarian Cancer
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Lung Cancer
• Cervical Cancer
• Others
By Treatment
• Chemotherapy
• Targeted Therapy
• Radiotherapy
• Others
By End-users
• Hospitals & Specialty Clinics
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the silent cancer therapeutics market include F. Hoffmann-La Roche Ltd, Amgen Inc, Merck & Co., Inc, AstraZeneca, AbbVie Inc, Pfizer Inc, GSK plc, Takeda Pharmaceutical Company Limited, Novartis AG and Bristol Myers Squibb Company.
Key Developments
 In April 2024, Researchers at IIT Madras patented Indian spice-based Nanomedicines for cancer treatment. The formulations show anti-cancer activity against lung, breast, colon, cervical, oral, and thyroid cell lines but were safe in normal cells.
 In July 2023, Ruby Hall Clinic and Bajaj Finserv introduced the CyberKnife S7, a robotic radiotherapy system. The technology, inaugurated by Bhagwat Karad, Minister of State of Finance, Government of India, and Chandrakant Patil, Minister of Higher and Technical Education of Maharashtra, improves cancer treatment with precise, non-invasive radiation therapy for tumor targeting.
 In July 2023, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) was approved in China as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
Why Purchase the Report?
• To visualize the global silent cancer therapeutics market segmentation based on cancer type, treatment, end-users, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of silent cancer therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global silent cancer therapeutics market report would provide approximately 62 tables, 62 figures, and 182 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Cancer Type
3.2. Snippet by Treatment
3.3. Snippet by End-users
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Silent Cancer
4.1.1.2. Advancements in Cancer Research
4.1.2. Restraints
4.1.2.1. High Treatment Cost
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Cancer Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
6.1.2. Market Attractiveness Index, By Cancer Type
6.2. Ovarian Cancer *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Breast Cancer
6.4. Prostate Cancer
6.5. Colorectal Cancer
6.6. Lung Cancer
6.7. Cervical Cancer
6.8. Others
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Market Attractiveness Index, By Treatment
7.2. Chemotherapy *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Targeted Therapy
7.4. Radiotherapy
7.5. Others
8. By End-users
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
8.1.2. Market Attractiveness Index, By End-users
8.2. Hospitals & Clinics *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ambulatory Surgical Centers
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. F. Hoffmann-La Roche Ltd *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Amgen Inc
11.3. Merck & Co., Inc
11.4. AstraZeneca
11.5. AbbVie Inc
11.6. Pfizer Inc
11.7. GSK plc
11.8. Takeda Pharmaceutical Company Limited
11.9. Novartis AG
11.10. Bristol Myers Squibb Company
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us